Ocular Therapeutix, a Bedford, MA-based developer of therapies for the eye, has brought in an additional $6 million for its Series C round, which now totals $21 million, company co-founder and CEO Amar Sawhney confirmed via e-mail today. The SEC posted a record of the financing on its website today. The company, previously known as I-Therapeutix, announced the previous $15 million close of its third round led by Polaris Venture Partners of Waltham, MA in June 2009. Ocular is advancing hydrogel technology for protecting the eye after ophthalmic surgeries and for delivering drugs to the eye.
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
